Ratings TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
15.9 ^USD	+0.32%		-2.63%	-6.91%

May. 01	Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	MT
May. 01	Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the past year, analysts have significantly revised downwards their profit estimates.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
TG THERAPEUTICS, INC.	-6.91%	2.28B	C-
MODERNA, INC.	+49.41%	56.95B	B-
LONZA GROUP AG	+39.89%	40.26B	A
IQVIA HOLDINGS INC.	-6.72%	39.32B	B
CELLTRION, INC.	-5.96%	28.37B	C
ICON PUBLIC LIMITED COMPANY	+12.99%	26.45B	B-
ALNYLAM PHARMACEUTICALS, INC.	-19.82%	19.41B	B
MEDPACE HOLDINGS, INC.	+32.35%	12.54B	C+
BIO-TECHNE CORPORATION	-0.08%	12.15B	B+
UNITED THERAPEUTICS CORPORATION	+25.18%	12.21B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes